Gene signatures predict doxorubicin response in K9 osteosarcoma

Sunday, April 19, 2015 - 18:30 in Health & Medicine

There are two chemotherapies commonly used to treat bone cancer in dogs: doxorubicin and carboplatin. Some dogs respond better to one drug than to the other. But until now, the choice has been left largely to chance. New work by University of Colorado Cancer Center members at Colorado State University Flint Animal Cancer Center presented today at the American Association for Cancer Research (AACR) Annual Meeting 2015 demonstrates a gene expression model that predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to better choose which drug to use with their patients. The approach is adopted from and further validates a model known as COXEN (CO-eXpression gEne aNalysis), developed at the CU Cancer Center by center director Dan Theodorescu, MD, PhD, which is currently in clinical trials to predict the response of human tumors to drugs.

Read the whole article on Biology News Net

More from Biology News Net

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net